HEPATOCELLULAR CARCINOMA

This early-stage trial tests a DNA vaccine for people with long-term hepatitis C infection. The vaccine is designed to help the immune system recognize and attack the virus, potentially lowering the risk of liver cancer. About 33 adults with chronic hepatitis C will receive the v…

This study tests how well the drugs atezolizumab and bevacizumab work together in people with liver cancer or non-small cell lung cancer that has spread to the liver. About 36 adults will receive the drugs and be monitored for how long their cancer stays under control. Researcher…

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) with or without a targeted therapy (lenvatinib) to a standard procedure called TACE can help people with liver cancer that cannot be surgically removed. About 760 participants will be randomly a…

This study tests whether adding two drugs (camrelizumab and rivoceranib) to a standard procedure called TACE can help people with incurable liver cancer live longer without their disease getting worse. About 423 adults with liver cancer that cannot be removed by surgery are takin…

This study tests whether a combination of two drugs, cabozantinib and atezolizumab, works better than the standard drug sorafenib for people with advanced liver cancer who haven't had other treatments. About 837 adults took part. The goal is to see if the combo slows cancer growt…

This study tests whether adding the drug lenvatinib before and after a standard tumor-burning procedure (ablation) can prevent liver cancer from returning in patients at high risk of recurrence. About 32 adults with early-stage liver cancer that has aggressive features (like high…

This study tests whether adding a liver-directed chemotherapy infusion (FOLFOX-HAIC) to a two-drug immunotherapy regimen (camrelizumab plus apatinib) helps people with advanced liver cancer that has invaded the portal vein live longer. About 214 adults who have not had prior syst…

This study tests a device that uses sound waves (histotripsy) to break apart liver tumors without needles or surgery. It includes 24 adults with liver cancer or tumors that have spread to the liver. The goal is to see if the treatment is safe and completely covers the tumor.

This early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…

This study tests a new treatment called AZD5851 for adults with advanced or recurrent liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals are t…

This early-stage study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) can improve outcomes for people with advanced liver cancer that cannot be removed by surgery. About 43 adults with unresectable hepatocell…

This study tests a new device that uses sound waves (histotripsy) to break apart liver tumors without needles or surgery. About 47 adults with liver cancer or tumors that spread to the liver will receive this treatment. The goal is to see if the device can safely and completely d…

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus radiation therapy for people with advanced liver cancer (hepatocellular carcinoma) or bile duct cancer (biliary tract cancer). The goal is to see how many patients' tumors shrink or disap…

This study tested two immune-boosting drugs, durvalumab and tremelimumab, alone or together, in 433 adults with advanced liver cancer that had stopped responding to standard treatment. The goal was to see if these drugs could shrink tumors and how safe they were. While not a cure…

This study tests an experimental immunotherapy called AlloStim against standard treatments (Sorafenib, Lenvatinib, or FOLFOX4) in 150 Asian adults with advanced liver cancer that cannot be treated with surgery or local therapies. The main goal is to see if AlloStim helps people l…

This study tests whether the drug nivolumab can help keep liver cancer from returning after surgery or ablation in people at high risk of recurrence. About 545 participants will receive either nivolumab or a placebo, and researchers will track how long they stay cancer-free. The …

This early-phase study tests a new treatment called BOXR1030, which uses specially designed immune cells to target a protein (GPC3) found on certain advanced solid tumors. The study involves 7 adults with liver, lung, skin, or soft tissue cancers that have not responded to standa…

This study tests whether adding a new drug called tiragolumab to two existing drugs (atezolizumab and bevacizumab) can help control advanced liver cancer better than the two-drug combo alone. About 687 adults with untreated, advanced liver cancer that cannot be removed by surgery…

This study tests a new combination of three drugs (casdozokitug, toripalimab, and bevacizumab) in 72 people with advanced liver cancer that cannot be removed by surgery. The main goals are to see if the combination is safe and shrinks tumors. Participants must have measurable tum…

This early-stage study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before and after surgery is safe and helps patients with liver cancer that can be removed. About 31 adults with resectable liver cancer will receive the drugs, then undergo surger…

This study looks at a new type of electrode (Octopus MP) used in radiofrequency ablation to treat small liver cancers (3 cm or smaller). The goal is to see how well it destroys tumors and how often cancer comes back at the treatment site. About 76 adults with liver disease (like …

This study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…

This study tests a combination of three drugs (durvalumab, tremelimumab, and lenvatinib) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 114 participants will receive the drugs to see if they can slow cancer growth and improve…

This study tests a new oil called T-ACE Oil for people with liver cancer that cannot be removed by surgery. The oil is injected into the liver's blood vessels to block them and deliver treatment directly to the tumor. The trial aims to check if the oil is safe and works better th…

This early-stage study aimed to find the safest dose of NP-101, a drug made from black seed, when given alongside standard radiation therapy (Y-90) for people with liver cancer that cannot be surgically removed. The goal was to see if NP-101 could boost the immune system to impro…

This study tests whether adding focused radiation to a standard liver cancer treatment (chemoembolization) can better control the disease in patients waiting for a liver transplant. The goal is to keep the cancer from growing so the patient can successfully receive a new liver. T…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …

This study tests whether adding immunotherapy drugs (durvalumab with or without bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 adults with liver cancer that cannot be surgically removed will participate. The goal is to…

This phase 3 study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with advanced liver cancer live longer than current standard treatments (sorafenib or lenvatinib). About 732 participants who have not had prior systemic therapy are …

This study tests whether adding doxorubicin to sorafenib can help people with advanced liver cancer whose disease got worse while taking sorafenib alone. About 30 adults with confirmed liver cancer and mild or no cirrhosis will receive the combination. The goal is to see if the c…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This study tests a two-step treatment for liver cancer. First, tiny radioactive beads are injected into the liver to destroy tumors. Then, two immunotherapy drugs (durvalumab and tremelimumab) are given to help the immune system fight any remaining cancer. The goal is to see how …

This study tests a new drug (ABSK-011) combined with atezolizumab or standard treatments in about 118 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors, especially in patients whose cancers hav…

This early-phase trial tests a cancer vaccine (IMA970A) plus an immunotherapy drug (durvalumab) in about 10 people with very early to intermediate liver cancer who have already had standard treatments. The goal is to see if the combination is safe and can help lower the chance of…

This study tests whether the drug durvalumab, alone or with bevacizumab, can keep liver cancer from returning after surgery or ablation. About 900 people who had their liver cancer removed but are at high risk of recurrence will receive either the study drugs or a placebo. The go…

This study tests whether giving a short course of focused radiation along with two immunotherapy drugs (atezolizumab and bevacizumab) before surgery can safely shrink liver cancer and improve outcomes. About 20 adults with resectable liver cancer will receive this combination, th…

This study tests whether combining three drugs (durvalumab, bevacizumab, tremelimumab) with a liver procedure called TACE can help people with advanced liver or bile duct cancer live longer without their cancer growing. About 27 adults with intermediate or advanced liver cancer o…

This early-stage trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug h…

This study tests a treatment called Eye90 microspheres for people with liver cancer that cannot be removed by surgery. The tiny beads deliver radiation directly to tumors to shrink them. The trial involves 120 participants and measures how well the tumors respond and how safe the…

This study tests whether adding an experimental drug (VIC-1911) to a standard targeted therapy (lenvatinib) can safely shrink tumors and slow disease progression in people with advanced liver cancer. About 12 adults aged 18-75 with stage C liver cancer and good liver function wil…

This study tests whether lisinopril, a widely used blood pressure medication, can slow the progression of non-alcoholic fatty liver disease (NAFLD) and lower the risk of liver cancer. About 45 adults with advanced liver scarring (fibrosis) will take lisinopril for a period, and r…

This study tests whether giving the drug cemiplimab (alone or with fianlimab) before surgery can shrink tumors in people with lung, liver, or head/neck cancers. About 65 participants will receive the drug and then have surgery to remove their cancer. Researchers will check how mu…

This study is for adults with advanced liver cancer. It compares two treatment plans after a procedure that delivers radiation beads (Therasphere) into the liver: one group gets immunotherapy (atezolizumab and bevacizumab), the other gets targeted pills (lenvatinib or cabozantini…

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE works better than TACE alone. About 342 adults with liver cancer that hasn't spread outside the liver and who are at high risk of poor results f…

This study tests whether adding the experimental drug nofazinlimab to standard lenvatinib therapy helps people with advanced liver cancer live longer. About 534 adults who cannot have surgery or other local treatments will receive either the combo or a placebo plus lenvatinib. Th…

This study tests a gradual dose increase of the drug regorafenib in 28 adults with advanced liver cancer who have already tried other treatments. The goal is to see if starting at a lower dose and slowly raising it helps patients handle the drug better and complete more cycles of…

This study tests a combination of two drugs, pembrolizumab and bavituximab, in people with advanced liver cancer that cannot be treated with surgery or local therapies. About 35 participants will receive the treatment to see how many respond and how safe it is. The goal is to fin…

This study looks at whether surgery to remove liver cancer helps people live longer when the cancer has completely disappeared after drug therapy. It includes 729 adults aged 18-75 whose cancer was initially too advanced for surgery. The goal is to see if surgery improves surviva…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…

This large Phase 3 trial tested whether two immunotherapy drugs (durvalumab and tremelimumab) work better than the standard treatment (sorafenib) for advanced liver cancer that cannot be surgically removed. The study involved 1,324 adults with advanced liver cancer who had not re…

This study uses CT scans and artificial intelligence (AI) to find liver cancer earlier. Researchers will analyze images from 10,000 patients with confirmed liver tumors. The AI helps outline tumors, and doctors check the results to improve accuracy. The goal is to create a better…

This study looks at whether using two contrast agents in MRI scans can help doctors find and tell apart noncancerous and cancerous liver spots more accurately. About 100 adults with recent abdominal MRIs will get an extra scan with two dyes. The goal is to improve diagnosis witho…

This study is testing a new blood test called Oncoguard™ Liver to see how well it finds liver cancer early in people who are at high risk, such as those with cirrhosis or hepatitis B. About 2,990 adults will take part, and the test's accuracy will be compared to standard ultrasou…

This study tests whether simvastatin, a widely used cholesterol medication, can stop liver cancer from developing in people with liver cirrhosis. About 52 adults with confirmed cirrhosis will take simvastatin, and researchers will measure changes in blood markers linked to liver …

This early-stage trial is testing how safe radiation therapy is for people with liver cancer who also have liver damage from cirrhosis, chemotherapy, or surgery. The goal is to find the best dose that can kill cancer cells without causing severe side effects. The study includes 3…

This study follows over 2,700 patients with bladder, lung, or liver cancer who received the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls the cancer outside of strict clinical trial settings. The goa…

This study tests whether an automatic reminder in the medical record helps doctors order liver ultrasounds for cirrhosis patients who need screening for liver cancer. About 1,300 adults with cirrhosis will take part. The goal is to see if the reminder increases the number of comp…

This early-phase study tests a new imaging agent called 68Ga-FAPI-46, which targets cells around tumors. About 26 adults with various cancers will receive the tracer and then have a PET/CT scan. The goal is to see where the tracer goes in the body and compare it to standard imagi…

This study collects blood, urine, stool, and tissue samples from 132 adults with liver cancer who have had or will have immunotherapy. The goal is to build a large collection of samples and health data to better understand how liver cancer develops and responds to treatment. Part…

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of people who attend regular liver cancer (HCC) ultrasound screenings. The study includes 652 adults with liver cirrhosis or chronic hepatitis B who are at high risk for l…

This study tests a new decision aid tool to help VA medical centers adopt proven methods for screening patients with cirrhosis for liver cancer. About 8,020 veterans and clinicians will take part. The goal is to see if the tool improves screening rates, cancer detection, and long…

This study compares two types of catheters used during a mapping step before liver cancer treatment. The goal is to see if a pressure-enabled device delivers more radioactivity directly to tumors than a standard catheter. Twenty adults with liver cancer will each receive both cat…

This study follows 1000 adults with liver cancer (hepatocellular carcinoma) who receive a liver transplant. Researchers will track how long patients stay cancer-free and how long they live overall. The goal is to find patterns that predict whether the cancer will come back after …